BioSpace News Archive

IDRx, Inc. announced that it has strengthened its leadership team with the appointments of Tim Clackson, Ph.D. as Chief Executive Officer, and Brad Dahms as Chief Financial Officer and Chief Business Officer.

Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages.

SciSparc Ltd. announced that MitoCareX Bio Ltd., the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, revealed that millions of small molecules were virtually screened using its computationally advanced drug discovery platform, with several molecules identified as potential anti-cancer treatments.

GenScript Biotech Corporation (HK.1548), a world’s leading technology and service provider of life science R&D and manufacturing, announced its annual results for the year ended December 31, 2023.

Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, announced a partnership with Mark Cuban Cost Plus Drug Company, PBC to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.

Coya Therapeutics, Inc. will present biomarker data today as part of a panel presentation at the Society of Neuroimmune Pharmacology Conference.

SOTIO Biotech today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.

Natera, Inc. today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.

Venatorx Pharmaceuticals announced expansion of its leadership team with three key industry veterans: Jason Burdette joining as Senior Vice President, CMC and Technical Operations: Armand Girard as Chief Business Officer; and Tamra Adams, and Chief Financial Officer.